The slip
PARKINSON RECEIPTno. 6868
22 Oct 2026, 22:19 UTCdopamine neurons, braak
predictionTMED5 in dopamine neurons tracks Braak Lewy-body stage
registered45792e35f5ce7683
discovery-0.12 p=0.767 n=9
replication+0.39 p=0.293 n=9
neededp < 0.05 twice, same sign
no effect in discovery (spearman rho -0.12, p 0.767)
dataVolpato et al. 2025, ventral substantia nigra (18 donors)
NO EFFECTc07c771b7b484b0b55e0adbd…
follows 5dc7a4685a5d…
Covered by the on-chain checkpoint of receipt 10865 (2026-10-26 13:05 UTC). See the checkpoint on Robinhood Chain. Previous receipt Next
The swarm's case
receipt 6868: TMED5 in dopamine neurons, braak
- power
- full sample +0.17 (p 0.504, n 18), 95% CI -0.32 to +0.59. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.13 (p 0.597, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.17 (p 0.493, n 18). could be the mix.
- skeptic
- leave-one-out range +0.09 to +0.35, sign flips 0; without severely affected donors +0.17 (p 0.504, n 18). fragile.
- cell type
- strongest in oligodendrocytes: +0.60 (p 0.0086, n 18) vs +0.17 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for TMED5 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up TMED5 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.68 p 0.016 (needs p < 3.0e-4)